Private Institute Briefs

Patent Protection For Worcester Discovery In an effort to speed the development of anti-AIDS drugs—and, perhaps, to profit in the process—the Worcester Foundation for Experimental Biology has patented a class of substances known as anti-sense DNA.” These are pieces of synthetic DNA that have the ability to enter cells and “lock on” to the genes of a virus. The patent, received Feb. 21, is for work conducted by institution scientists Paul C. Zamecnik and John Goodc

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In an effort to speed the development of anti-AIDS drugs—and, perhaps, to profit in the process—the Worcester Foundation for Experimental Biology has patented a class of substances known as anti-sense DNA.” These are pieces of synthetic DNA that have the ability to enter cells and “lock on” to the genes of a virus. The patent, received Feb. 21, is for work conducted by institution scientists Paul C. Zamecnik and John Goodchild showing that anti-sense DNA could inhibit the replication of the AIDS virus in human cells grown in the laboratory. This research was published in the Proceedings of the National Academy of Sciences (volume 83, pages 4143-6, 1986). Although the patented world is still far from producing a cure for AIDS, the institute is actively seeking a collaborator from the pharmaceutical industry for further development of these drugs.

Both the patent and the aggressive search for a collaborator reflect the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies